Arlington Partners LLC raised its position in Relx Plc (NYSE:RELX - Free Report) by 9.5% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 91,833 shares of the technology company's stock after acquiring an additional 7,943 shares during the period. Arlington Partners LLC's holdings in Relx were worth $4,171,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. WCM Investment Management LLC increased its position in shares of Relx by 86.7% in the fourth quarter. WCM Investment Management LLC now owns 48,035 shares of the technology company's stock valued at $2,181,000 after acquiring an additional 22,308 shares during the last quarter. Entropy Technologies LP bought a new position in Relx in the fourth quarter valued at approximately $217,000. Cidel Asset Management Inc. increased its position in shares of Relx by 6.5% during the 4th quarter. Cidel Asset Management Inc. now owns 16,666 shares of the technology company's stock worth $757,000 after purchasing an additional 1,022 shares during the last quarter. Bleakley Financial Group LLC raised its stake in shares of Relx by 12.4% during the 4th quarter. Bleakley Financial Group LLC now owns 13,940 shares of the technology company's stock worth $633,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Choreo LLC boosted its holdings in shares of Relx by 3.6% in the 4th quarter. Choreo LLC now owns 20,106 shares of the technology company's stock valued at $913,000 after buying an additional 702 shares during the last quarter. Institutional investors and hedge funds own 15.02% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on RELX. Redburn Atlantic initiated coverage on shares of Relx in a report on Wednesday, January 8th. They set a "buy" rating on the stock. StockNews.com started coverage on shares of Relx in a research report on Wednesday, October 30th. They issued a "hold" rating for the company.
Read Our Latest Report on Relx
Relx Stock Performance
NYSE:RELX traded up $0.53 on Monday, hitting $50.52. The company's stock had a trading volume of 365,927 shares, compared to its average volume of 573,047. The company has a debt-to-equity ratio of 1.63, a current ratio of 0.48 and a quick ratio of 0.42. Relx Plc has a one year low of $40.25 and a one year high of $50.84. The stock has a fifty day moving average of $47.45 and a two-hundred day moving average of $47.00.
Relx Profile
(
Free Report)
RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.
Read More
![Institutional Ownership by Quarter for Relx (NYSE:RELX)](https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&Symbol=RELX)
Before you consider Relx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relx wasn't on the list.
While Relx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.